Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00919035 · ClinicalTrials.gov registry record · Phase 2
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
A Phase 2 study, sponsored by Oncology Specialists, S.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00919035 is a Phase 2 study that has completed, run by Oncology Specialists, S.C.. The registered enrollment target is 21 participants.
The verdict
NCT00919035, a Phase 2 study, has completed, sponsored by Oncology Specialists, S.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a single institution, open label, phase II study in androgen-independent prostate cancer patients who are chemotherapy-naïve. Patients will receive Torisel® 25 mg weekly. Treatment continues until disease progression, patient's withdrawal, unacceptable toxicity or the investigator's discretion.
Interventions
- DRUG torisel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2009-06 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00919035
The ClinicalTrials.gov registry entry for NCT00919035 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oncology Specialists, S.C., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which torisel is the first listed.
NCT00919035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00919035 about?
NCT00919035 is a clinical study titled "Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients". This is a single institution, open label, phase II study in androgen-independent prostate cancer patients who are chemotherapy-naïve. Patients will receive Torisel® 25 mg weekly. Treatment continues until disease progression, patient's withdrawal, unacceptable toxicity or the investigator's discreti...
What is the current status of trial NCT00919035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2009-06. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00919035?
The interventions under investigation include: torisel (DRUG).
Who is sponsoring clinical trial NCT00919035?
This trial is sponsored by Oncology Specialists, S.C., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.